On December 1, 2017, Hansoh Pharmaceutical Group’s official WeChat account posted a news article named “Blockbuster: China Approves First-to-market Generic of Bortezomib (Xintai) of Hansoh Pharma!”. Number of clicks has so far exceeded 10,000, owing to bortezomib’s excellent clinical performance as well as domestic patients’ trust in the quality of Hansoh’s products.
As a lifesaver, Xintai has attracted wide attention from domestic multiple myeloma (MM) patients.
MM is the second most prevalent malignant tumor of hematologic system. There are at least hundreds of thousands of MM patients across the world (based on analysis of reports on yaozh.com). MM has an extremely high fatality rate and is a nightmare for every patient. Foreign researches show that bortezomib-based treatment has a rate of response of 78%-100%, making it the first choice for treating such diseases.
“Before Xintai got approval, domestic price of originator drug stayed high. Many MM patients in China could not afford expensive treatment and had to choose less effective solution or even give up.” Says an expert from Xintai’s R&D team. “Domestic patients, out of the desire for recovery and survival, had been closely following the approval process of bortezomib (Xintai), prompting CFDA’s Center for Drug Evaluation (CDE) to incorporate Xintai into the list of priority review list in 2016.”
Besides, bortezomib has also been granted approval for treatment of indications of relapsed/refractory MCL, and recommended by a foreign handbook to be used in treatment of T cell lymphoma and other refractory tumors.
Hansoh products are undisputedly excellent. That is why Xintai has attracted so much attention.
“The quality standards of Xintai is highly consistent with that of originator drug.” Says quality control technician from Hansoh’s modernized production facilities. Xintai’s production technology is very complex. After countless technological breakthroughs, scientists finally successfully developed stable bortezomib lyophilized powder injectable preparations.
In the corridor of Xintai’s workshop, we witnessed the production process and also got to know that freeze-fried powder is a hi-tech dosage form and has very high requirements for sterilization. Xintai is a sterile injectables produced on A-level laminar-flow sterile filling lines. (Note: A-level is the highest cleanliness level under GMP).
Due to Xintai’s unique preparation process, its freeze-dried powder injection technology obtained patent for invention from State Intellectual Property Office (SIPO) in January, which is also an important testimony of Hansoh’s excellent quality.
It was understood that with the mission of “serve the society and build a healthy world”, Hansoh’s production staff are working hard to help improve the health condition of MM and MCL patients and cast a ray of sunshine into their life.
Xintai is a representation of the brave Hansohers’ pursuit of excellence. They have always been on the journey to improve Chinese people’s health and life through technology innovation. We believe that encouraged by innovative technologies, Chinese patients will be able to bravely face illness and blaze a trail to survival and health.
On February 4th, 2018, the first launch ceremony of Xintai will be held in Beijing. We will continue to follow and cover updates.
